Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  radium ra 223 dichloride
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Phase: Phase II, Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0952, NCI-2013-02267, ONC-2012-66, NCT01833520
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16507, NCI-2014-01605, 2013-003118-42, NCT02023697
Radium Ra 223 Dichloride and Enzalutamide in Treating Patients with Metastatic Prostate Cancer That Is Resistant to Antihormone Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI68770, NCI-2014-01823, NCT02199197
Radium Ra 223 Dichloride in Reducing Pain in Patients with Symptomatic Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-098, NCI-2014-02542, c13-124, NCT02278055
Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-375, NCI-2015-00625, ONC-2013-119, NCT02346526
Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0508, NCI-2015-00508, NCT02366130
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 18 and over
Trial IDs: 16913, NCI-2014-02038, NCT02141438
Radium Ra 223 Dichloride with Pazopanib Hydrochloride or Sorafenib Tosylate in Treating Patients with Metastatic Kidney Cancer and Bone Metastases
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 14-523, NCI-2015-00915, ONC-2014-092, NCT02406521
Start Over